Successful management of an outbreak due to carbapenem-resistant Acinetobacter baumannii in a neonatal intensive care unit

Eur J Pediatr. 2015 Jan;174(1):65-74. doi: 10.1007/s00431-014-2365-8. Epub 2014 Jul 2.

Abstract

The investigation and successful management of a monoclonal Acinetobacter baumannii outbreak in a neonatal intensive care unit are described. Upon the first clustered carbapenem-resistant A. baumannii (CRAB) infections, a bundle of actions were taken, including enhanced infection control, active surveillance (weekly stool samples), case-control study, staff education, daily audits and discontinuation of new admissions. Between September and December 2011, eight neonates developed 10 CRAB infections (five blood, four respiratory and one eye). A total of 216 active surveillance cultures were obtained from 96 neonates (43 % had ≥2 samples). During weeks 12, 16 and 17, active surveillance detected 3, 1 and 2 new CRAB acquisitions, respectively. Prevalence of infections/colonizations decreased, and no event occurred after 20th week. A colonized neonate developed CRAB sepsis and died. All CRAB isolates harboured bla OXA-58 and the intrinsic chromosomal bla OXA-51 carbapenemase genes.

Conclusion: Active surveillance and enhanced infection control measures effectively contained spread of CRAB clone in the neonatal intensive care unit.

Publication types

  • Clinical Trial

MeSH terms

  • Acinetobacter Infections / drug therapy*
  • Acinetobacter Infections / epidemiology*
  • Acinetobacter Infections / microbiology
  • Acinetobacter baumannii / drug effects
  • Acinetobacter baumannii / genetics
  • Acinetobacter baumannii / isolation & purification*
  • Anti-Bacterial Agents / therapeutic use
  • Carbapenems / adverse effects
  • Colistin / therapeutic use
  • Disease Outbreaks*
  • Feces / microbiology
  • Humans
  • Infant, Newborn
  • Intensive Care Units, Neonatal
  • Meropenem
  • Prospective Studies
  • Thienamycins / therapeutic use
  • beta-Lactam Resistance*
  • beta-Lactamases / genetics

Substances

  • Anti-Bacterial Agents
  • Carbapenems
  • Thienamycins
  • beta-Lactamases
  • beta-lactamase OXA-51, Acinetobacter baumannii
  • beta-lactamase OXA-58, Acinetobacter baumannii
  • Meropenem
  • Colistin